DDW

Resources and insights tagged ddw from Pedestal Health.

Publications

Impact of Early Endoscopic Remission After Advanced Therapy on Long-Term Complications in Crohn's Disease: Findings From Target-IBD

Early Endoscopic Remission Predicts Fewer Long-Term Complications in Ulcerative Colitis: Real-World Analysis From Target-IBD Registry

University of Colorado Anschutz Medical Campus

Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis

University of North Carolina at Chapel Hill University of Wisconsin

Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort

AbbVie Inc.University of North Carolina at Chapel Hill Cleveland Clinic

Biologic-naïve Patients with Crohn's Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort

Total Publications

Oral Presentation

Poster Presentation

2026 · Poster Presentation · Gastroenterology

Impact of Early Endoscopic Remission After Advanced Therapy on Long-Term Complications in Crohn's Disease: Findings From Target-IBD

2026 · Poster Presentation · Gastroenterology

Early Endoscopic Remission Predicts Fewer Long-Term Complications in Ulcerative Colitis: Real-World Analysis From Target-IBD Registry

2022 · Poster Presentation · University of Colorado Anschutz Medical Campus · Gastroenterology

Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis

2021 · Poster Presentation · University of North Carolina at Chapel Hill · Gastroenterology

Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort

2021 · Poster Presentation · AbbVie Inc. · Gastroenterology

Biologic-naïve Patients with Crohn's Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort

2020 · Oral Presentation · Gastroenterology

Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD

2020 · Oral Presentation · Hepatology

Weight Loss and Change in Alanine Aminotransferase (ALT) Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Receiving Standard Care in Real World Clinical Practice: TARGET-NASH

2019 · Poster Presentation · University of Miami (FL) · Hepatology

Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real-world cohort (DDW 2019)

2019 · Poster Presentation · University of Miami (FL) · Hepatology

Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort (DDW 2019)

2018 · Poster Presentation · University of Michigan · Hepatology

Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH

2018 · Poster Presentation · University of Michigan · Hepatology

Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease (DDW)

2018 · Poster Presentation · Stanford · Hepatology

Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC (DDW)

2018 · Poster Presentation · Stanford · Hepatology

Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC (DDW)

2017 · Poster Presentation · University of Michigan · Hepatology

DDW

Publications

Impact of Early Endoscopic Remission After Advanced Therapy on Long-Term Complications in Crohn's Disease: Findings From Target-IBD

Early Endoscopic Remission Predicts Fewer Long-Term Complications in Ulcerative Colitis: Real-World Analysis From Target-IBD Registry

Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis

Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort

Biologic-naïve Patients with Crohn's Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort

Impact of Early Endoscopic Remission After Advanced Therapy on Long-Term Complications in Crohn's Disease: Findings From Target-IBD

Early Endoscopic Remission Predicts Fewer Long-Term Complications in Ulcerative Colitis: Real-World Analysis From Target-IBD Registry

Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis

Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort

Biologic-naïve Patients with Crohn's Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort

Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD

Weight Loss and Change in Alanine Aminotransferase (ALT) Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Receiving Standard Care in Real World Clinical Practice: TARGET-NASH

Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real-world cohort (DDW 2019)

Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort (DDW 2019)

Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH

Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease (DDW)

Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC (DDW)

Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC (DDW)

Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH